Antimicrobial peptides as potential new antifungals

Frank Michael C Müller, C. A. Lyman, T. J. Walsh

Research output: Contribution to journalArticle

Abstract

Ribosomally synthesized natural antimicrobial peptides (AP) and their synthetic derivatives are small, cationic, amphipathic molecules of 12-50 amino acids with unusually broad activity spectra. These peptides kill microorganisms by a common mechanism, which involves binding to the lipid bilayer of biological membranes, forming pores, and ultimately followed by cell lysis. Several AP from mammals, amphibians, insects, plants and their synthetic derivatives demonstrate promising in vitro activity against various pathogenic fungi including azole-resistant Candida albicans strains. In addition to their antimicrobial activity, some AP such as lactoferrin, interact with a variety of host cells and can increase the activity of natural killer and lymphokine activated killer cells. Pretreatment of polymorphonuclear neutrophil leukocytes (PMN) or monocytes with these AP also may upregulate superoxide release. AP as potential new antifungal agents offer some advantages, such as rapid killing of pathogenic fungi and the difficulty to raise mutants resistant to these peptides. AP are limited by their nonselective toxicity, stability, immunogenicity and their costs of production. Potential clinical applications of AP in the future have to be further explored in preclinical and clinical studies to assess their impact as a new class of antifungals.

Original languageEnglish (US)
Pages (from-to)77-82
Number of pages6
JournalMycoses, Supplement
Volume42
Issue number2
StatePublished - 1999
Externally publishedYes

Fingerprint

Peptides
Neutrophils
Fungi
Lymphokine-Activated Killer Cells
Azoles
Lactoferrin
Antifungal Agents
Population Growth
Lipid Bilayers
Amphibians
Candida albicans
Superoxides
Insects
Monocytes
Mammals
Up-Regulation
Amino Acids
Costs and Cost Analysis
Membranes

Keywords

  • Antifungal activity
  • Antimicrobial activity
  • Host defense
  • Peptides
  • Synthetic derivatives

ASJC Scopus subject areas

  • Microbiology
  • Immunology

Cite this

Müller, F. M. C., Lyman, C. A., & Walsh, T. J. (1999). Antimicrobial peptides as potential new antifungals. Mycoses, Supplement, 42(2), 77-82.

Antimicrobial peptides as potential new antifungals. / Müller, Frank Michael C; Lyman, C. A.; Walsh, T. J.

In: Mycoses, Supplement, Vol. 42, No. 2, 1999, p. 77-82.

Research output: Contribution to journalArticle

Müller, FMC, Lyman, CA & Walsh, TJ 1999, 'Antimicrobial peptides as potential new antifungals', Mycoses, Supplement, vol. 42, no. 2, pp. 77-82.
Müller FMC, Lyman CA, Walsh TJ. Antimicrobial peptides as potential new antifungals. Mycoses, Supplement. 1999;42(2):77-82.
Müller, Frank Michael C ; Lyman, C. A. ; Walsh, T. J. / Antimicrobial peptides as potential new antifungals. In: Mycoses, Supplement. 1999 ; Vol. 42, No. 2. pp. 77-82.
@article{dc26a860ff8545fea1cf845f7213c9af,
title = "Antimicrobial peptides as potential new antifungals",
abstract = "Ribosomally synthesized natural antimicrobial peptides (AP) and their synthetic derivatives are small, cationic, amphipathic molecules of 12-50 amino acids with unusually broad activity spectra. These peptides kill microorganisms by a common mechanism, which involves binding to the lipid bilayer of biological membranes, forming pores, and ultimately followed by cell lysis. Several AP from mammals, amphibians, insects, plants and their synthetic derivatives demonstrate promising in vitro activity against various pathogenic fungi including azole-resistant Candida albicans strains. In addition to their antimicrobial activity, some AP such as lactoferrin, interact with a variety of host cells and can increase the activity of natural killer and lymphokine activated killer cells. Pretreatment of polymorphonuclear neutrophil leukocytes (PMN) or monocytes with these AP also may upregulate superoxide release. AP as potential new antifungal agents offer some advantages, such as rapid killing of pathogenic fungi and the difficulty to raise mutants resistant to these peptides. AP are limited by their nonselective toxicity, stability, immunogenicity and their costs of production. Potential clinical applications of AP in the future have to be further explored in preclinical and clinical studies to assess their impact as a new class of antifungals.",
keywords = "Antifungal activity, Antimicrobial activity, Host defense, Peptides, Synthetic derivatives",
author = "M{\"u}ller, {Frank Michael C} and Lyman, {C. A.} and Walsh, {T. J.}",
year = "1999",
language = "English (US)",
volume = "42",
pages = "77--82",
journal = "Mycoses, Supplement",
issn = "0943-7312",
publisher = "Wiley-Blackwell",
number = "2",

}

TY - JOUR

T1 - Antimicrobial peptides as potential new antifungals

AU - Müller, Frank Michael C

AU - Lyman, C. A.

AU - Walsh, T. J.

PY - 1999

Y1 - 1999

N2 - Ribosomally synthesized natural antimicrobial peptides (AP) and their synthetic derivatives are small, cationic, amphipathic molecules of 12-50 amino acids with unusually broad activity spectra. These peptides kill microorganisms by a common mechanism, which involves binding to the lipid bilayer of biological membranes, forming pores, and ultimately followed by cell lysis. Several AP from mammals, amphibians, insects, plants and their synthetic derivatives demonstrate promising in vitro activity against various pathogenic fungi including azole-resistant Candida albicans strains. In addition to their antimicrobial activity, some AP such as lactoferrin, interact with a variety of host cells and can increase the activity of natural killer and lymphokine activated killer cells. Pretreatment of polymorphonuclear neutrophil leukocytes (PMN) or monocytes with these AP also may upregulate superoxide release. AP as potential new antifungal agents offer some advantages, such as rapid killing of pathogenic fungi and the difficulty to raise mutants resistant to these peptides. AP are limited by their nonselective toxicity, stability, immunogenicity and their costs of production. Potential clinical applications of AP in the future have to be further explored in preclinical and clinical studies to assess their impact as a new class of antifungals.

AB - Ribosomally synthesized natural antimicrobial peptides (AP) and their synthetic derivatives are small, cationic, amphipathic molecules of 12-50 amino acids with unusually broad activity spectra. These peptides kill microorganisms by a common mechanism, which involves binding to the lipid bilayer of biological membranes, forming pores, and ultimately followed by cell lysis. Several AP from mammals, amphibians, insects, plants and their synthetic derivatives demonstrate promising in vitro activity against various pathogenic fungi including azole-resistant Candida albicans strains. In addition to their antimicrobial activity, some AP such as lactoferrin, interact with a variety of host cells and can increase the activity of natural killer and lymphokine activated killer cells. Pretreatment of polymorphonuclear neutrophil leukocytes (PMN) or monocytes with these AP also may upregulate superoxide release. AP as potential new antifungal agents offer some advantages, such as rapid killing of pathogenic fungi and the difficulty to raise mutants resistant to these peptides. AP are limited by their nonselective toxicity, stability, immunogenicity and their costs of production. Potential clinical applications of AP in the future have to be further explored in preclinical and clinical studies to assess their impact as a new class of antifungals.

KW - Antifungal activity

KW - Antimicrobial activity

KW - Host defense

KW - Peptides

KW - Synthetic derivatives

UR - http://www.scopus.com/inward/record.url?scp=0342369486&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0342369486&partnerID=8YFLogxK

M3 - Article

C2 - 10865909

AN - SCOPUS:0342369486

VL - 42

SP - 77

EP - 82

JO - Mycoses, Supplement

JF - Mycoses, Supplement

SN - 0943-7312

IS - 2

ER -